Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261806 | 0.87 | MAOB (0.48) | MAOBGAALTA4HTSHRAKR1C3 | |
| SCHEMBL28263208 | 0.85 | LTA4H (0.46) | FFAR4FFAR1LTA4HTSHRGSTP1 | |
| SCHEMBL61732 | 0.82 | LTA4H (0.57) | MAOBLTA4HTSHRGSTP1 | |
| SCHEMBL16361075 | 0.82 | LTA4H (0.55) | FFAR4FFAR1MAOBGAALTA4H | |
| SCHEMBL6099009 | 0.81 | FFAR4 (0.48) | FFAR4FFAR1MAOBGAALTA4H | |
| SCHEMBL2261470 | 0.81 | FFAR4 (0.48) | FFAR4FFAR1MAOBGAALTA4H | |
| SCHEMBL28072263 | 0.81 | LTA4H (0.55) | MAOBLTA4HTSHRGSTP1 | |
| SCHEMBL4536542 | 0.80 | LTA4H (0.60) | FFAR4FFAR1MAOBGAALTA4H | |
| SCHEMBL11409557 | 0.80 | LTA4H (0.52) | FFAR4FFAR1MAOBGAALTA4H | |
| SCHEMBL8155454 | 0.80 | LTA4H (0.43) | MAOBGAALTA4HTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071693-A | Resin combination is used in the formation of high refractive index cured film | 日产化学株式会社 | 2018-12-21 | — | — | CN | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | FFAR4 1139/4885FFAR1 744/4885MAOB 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.